Wave Life Sciences Ltd.

For the period ended Jun 30, 2026. Filed Jul 30, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Jul 30, 2026

WVE$3.48+3.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets

(In thousands, except share amounts)

	June 30, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$368,008	$602,068
Marketable securities	122,594	—
Accounts receivable	888	1,276
Prepaid expenses	12,121	8,395
Other current assets	3,897	3,075
Total current assets	507,508	614,814
Long-term assets:
Property and equipment, net of accumulated depreciation of $50,819 and $49,522 as of June 30, 2026 and December 31, 2025, respectively	6,833	7,405
Operating lease right-of-use assets	39,498	12,458
Restricted cash	3,815	3,806
Other assets	667	16
Total long-term assets	50,813	23,685
Total assets	$558,321	$638,499
Liabilities, Series A preferred shares, and shareholders’ equity
Current liabilities:
Accounts payable	$20,362	$15,700
Accrued expenses and other current liabilities	18,242	26,564
Current portion of deferred revenue	8,703	44,440
Current portion of operating lease liability	3,508	8,361
Total current liabilities	50,815	95,065
Long-term liabilities:
Deferred revenue, net of current portion	13,904	7,798
Operating lease liability, net of current portion	40,082	9,405
Total long-term liabilities	53,986	17,203
Total liabilities	$104,801	$112,268
Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	$—	$7,874
Shareholders’ equity:
Ordinary shares, no par value; 193,277,622 and 187,660,263 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	$1,627,209	$1,616,478
Additional paid-in capital	248,161	228,365
Accumulated other comprehensive loss	(172)	(250)
Accumulated deficit	(1,421,678)	(1,326,236)
Total shareholders’ equity	$453,520	$518,357
Total liabilities, Series A preferred shares, and shareholders’ equity	$558,321	$638,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.